Getting To A First Product Approval With Celcuity's Brian Sullivan

We love to hear from our listeners. Send us a message. (buzzsprout.com/1011661/fan_mail/new)
On this week's episode of the Business of Biotech, Brian Sullivan, CEO at Celcuity, talks about winning the company's first FDA approval for Revtorpyk, a kinase inhibitor for breast cancer patients, and why targeting an “untreated disease mechanism” can beat chasing a single mutation. Brian also discusses the process for licensing a shelved Pfizer asset for development, designing Phase 3 trials that challenge assumptions, the benefits of FDA's Real-Time Oncology Review, and managing downside risk while advancing new indications, all while building a launch-ready company without losing pipeline momentum.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (lifescienceleader.com/solution/the-business-of…) tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter (www9.lifescienceleader.com/business-of-biotech…).

Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

Find Ben Comer on LinkedIn: linkedin.com/in/bencomer